Observes acalabrutinib use in adults with chronic lymphocytic leukemia in Belarus
Studies how acalabrutinib is used in adults with chronic lymphocytic leukemia in routine care.
Plain-language title generated from the registry record
Registry title: Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Key facts
- Where
- Grodno, Homyel, Minsk, and Mogilev, BelarusSee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic lymphocytic leukemia (CLL) who were newly prescribed acalabrutinib alone, in the previous four weeks.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Confirmed CLL, either not treated before or relapsed or refractory (R/R) disease
- Earlier treatment
- Acalabrutinib newly prescribed within the previous four weeks as the only anti-leukemia medicine. No other anti-leukemia agent (for example obinutuzumab, venetoclax, bendamustine) within ± 30 days of starting. No earlier treatment with any BTK inhibitor.
Main reasons for not taking part
- Prior treatment with any BTK inhibitor
- Taking part in another ongoing clinical trial
- Pregnant or breastfeeding women
- Acalabrutinib given together with other anti-leukemia agents
Read by machine on 9 November 2026.
Where in Belarus
- GrodnoHospital not named in the registryTaking people
- HomyelHospital not named in the registryNot yet recruiting
- MinskHospital not named in the registryTaking people
- MogilevHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07288515
- Record updated
- 9 September 2026
- Original description
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLLRead full original descriptionShow less
Observational Prospective Study of Acalabrutinib in Chronic Lymphocytic Leukemia Therapy in Real Clinical Practice in Belarus.
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Inclusion: Age ≥18 years; Confirmed diagnosis of CLL; Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation; Treatment-naïve or R/R CLL; Ability and willingness to provide informed consent for study participation.
Exclusion: Prior treatment with any BTK inhibitor; Patients not satisfying any of the inclusion criteria; Participation in other ongoing clinical trials; Pregnant or breastfeeding females.